Bryan Wahl - 05 Mar 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: General Counsel
Signature: /s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 05 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Mar 2026, 16:06:55 UTC
Previous filing: 20 Mar 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wahl Bryan	General Counsel	C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE	/s/ Jeffrey Farrow, Attorney-in-Fact	09 Mar 2026	0001841401

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Stock Option (right to buy)	Award		+27,310		$0.000000^*	27,310	05 Mar 2026	Common Stock	27,310	$74.90	Direct	F1
transaction	TARS	Restricted Stock Units	Award		+17,161		$0.000000^*	17,161	05 Mar 2026	Common Stock	17,161		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
F2	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3	The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.